Clinical trials: Phospholamban R14del Mutation-related Cardiomyopathy

Phospholamban R14del Mutation-related Cardiomyopathy

PHOspholamban RElated CArdiomyopathy STudy - Intervention

• Completed
• Age: 30 to 65 years
• Phase 3

Phospholamban (PLN) R14del mutation carriers may develop dilated cardiomyopathy (DCM) and/or arrhythmmogenic cardiomyopathy (ACM).

Trial name

i-PHORECAST (NCT01857856)

Testing

Eplerenone

Where

4 sites in Netherlands

Volunteers

84 people

Sponsor

M.p. van den Berg, MD, PhD, professor in Cardiology